Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2023-07-06 00:00:00 ET · period of report 2023-07-05 · accession 0001209191-23-041583 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-06 | 2023-07-05 | KLRS | Brainard Diana | CEO, Dir | S - Sale | $3.05 | -5,275 | 915.6K | -0.6% | -$16.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-05 | S | D | 5,275 | $3.05 | 915,641 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.96 to $3.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. (F3) Includes 4,288 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2023. |